Base Editing (ABE8e) for GUCY2D c.2302C>T (p.Arg768Trp) in Leber congenital amaurosis 7 (GUCY2D-related)

Base Editing (ABE8e) via AAV delivery is a rationale-driven therapeutic strategy for Leber congenital amaurosis 7 (GUCY2D-related) targeting the GUCY2D c.2302C>T (p.Arg768Trp) variant (Pathogenic, missense variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: Eye/Retina. Therapeutic goal: Correct or supplement GUCY2D function in retinal photoreceptors to restore phototransduction and functional vision in GUCY2D-associated Leber congenital amaurosis.. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: GUCY2D NM_000180.4(GUCY2D):c.2302C>T (p.Arg768Trp) is classified as Pathogenic (ClinVar variation ID 98563). Molecular consequence: missense variant. Protein change: R768W. 2. Epidemiology: LCA overall prevalence is approximately 1/33,000-1/50,000 live births and accounts for around 5% of inherited retinal dystrophies and 20% of childhood blindness; GUCY2D is one of the more common molecular causes but exact LCA7 subtype prevalence is uncertain. Patients typically present in infancy wi 3. Standard of care: There is currently no approved disease-modifying or gene-specific therapy for GUCY2D-LCA7. Management is supportive and includes correction of refractive error, low-vision aids, educational and habilitation services, and treatment of complications such as cataract and keratoconus. Gene therapy is ap 4. Pipeline: An AAV-based subretinal gene augmentation therapy (ATSN-101) for GUCY2D-LCA is in Phase I/II clinical development with early evidence of clinically meaningful visual improvements (WEB-04, WEB-05, PAPER-14). Multiple AAV retinal gene therapies including RPE65 (voretigene) have reached Phase III and a 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting GUCY2D c.2302C>T (p.Arg768Trp) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically.
2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed.
3. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.